HC Wainwright Has Bearish Forecast for RNAC Q2 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Research analysts at HC Wainwright reduced their Q2 2025 EPS estimates for shares of Cartesian Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.68) per share for the quarter, down from their prior estimate of ($0.67). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is $4.56 per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ FY2025 earnings at ($2.80) EPS.

Cartesian Therapeutics (NASDAQ:RNAC) last issued its earnings results on Thursday, May 8th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.07). The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $0.69 million.

Separately, Needham & Company LLC decreased their price target on shares of Cartesian Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.50.

Cartesian Therapeutics Trading Down 9.3%

Shares of Cartesian Therapeutics stock opened at $9.28 on Wednesday. The company has a fifty day moving average price of $11.91 and a 200 day moving average price of $16.48. Cartesian Therapeutics has a twelve month low of $8.85 and a twelve month high of $41.87. The stock has a market cap of $240.85 million, a price-to-earnings ratio of -0.18 and a beta of 0.51.

Institutional Investors Weigh In On Cartesian Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of RNAC. 683 Capital Management LLC lifted its position in Cartesian Therapeutics by 20.0% during the 1st quarter. 683 Capital Management LLC now owns 150,000 shares of the company’s stock worth $1,977,000 after acquiring an additional 25,000 shares during the last quarter. MPM Bioimpact LLC lifted its position in Cartesian Therapeutics by 9.7% during the 1st quarter. MPM Bioimpact LLC now owns 790,779 shares of the company’s stock worth $10,422,000 after acquiring an additional 69,640 shares during the last quarter. AlphaQuest LLC acquired a new position in Cartesian Therapeutics during the 1st quarter worth $95,000. Erste Asset Management GmbH lifted its position in Cartesian Therapeutics by 49.8% during the 1st quarter. Erste Asset Management GmbH now owns 260,011 shares of the company’s stock worth $3,432,000 after acquiring an additional 86,445 shares during the last quarter. Finally, Twin Focus Capital Partners LLC lifted its position in Cartesian Therapeutics by 25.0% during the 1st quarter. Twin Focus Capital Partners LLC now owns 15,000 shares of the company’s stock worth $198,000 after acquiring an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 86.95% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.